FDA's Pazdur To Patient Advocates: Focus On Issues That 'Drive The Show'
This article was originally published in The Pink Sheet Daily
Agency's oncology office director reflects on his wife's experience with cancer and urges patient community to tackle 'big picture issues' like clinical trial eligibility and informed consent.
You may also be interested in...
US FDA drug reviewers argue that enrolling more heterogeneous patient populations could result in fewer postmarketing requirements and earlier satisfaction of pediatric study obligations.
Enrolling patients with stable brain metastases, HIV-positive status and other traditionally excluded groups could give sponsors a marketing edge, but trials should be designed to examine drug effects on such populations separately from the more traditional study population, stakeholders said.
With two weeks to go before hearing on whether the preterm birth prevention drug can stay on the market or be withdrawn, the lack of clarity on who will make the ultimate decision may stem from the lengthy duration of the dispute and multiple transitions within FDA’s senior leadership.